Veterinary injectable painless drug specifically for cats and dogs based on meloxicam with a convenient concentration
Vemelcam belongs to the nonsteroidal anti-inflammatory drugs of the oxicam group. It has a pronounced anti-inflammatory, analgesic and antipyretic effect.
The mechanism of action is based on the ability to inhibit the production of cyclooxygenase in the arachidonic acid cycle, suppressing mainly cyclooxygenase- II, under the influence of which the synthesis of inflammatory prostaglandins occurs, causing inflammation, swelling and pain.
Vemelcam is used in dogs and cats as an anti-inflammatory, antipyretic and analgesic agent for initial therapy and short-term symptomatic treatment:
|
Indicators |
Dogs |
Cats |
|
|
Dosage |
First administration - 0.1 ml per 1 kg of animal body weight (0.2 mg meloxicam per 1 kg of animal body weight), for following administrations - 0.05 ml per 1 kg of animal body weight (0.1 mg meloxicam per 1 kg of animal body weight) |
||
|
Method and frequency of administration |
Intramuscularly or subcutaneously, once every 24 hours |
||
|
Treatment period |
No more than 5 consecutive days |
No more than 3 consecutive days |
|
Contraindications and special instructions:
Hypersensitivity of animals to meloxicam, gastric ulcer and duodenal ulcer, severe renal, hepatic and heart failure, hemorrhagic syndrome, contraindicated in animals in a state of dehydration, hypovolemia and hypotension, due to the possible toxic effect of the veterinary drug on the kidneys. The veterinary drug is used with caution for kidney diseases.
It should not be used in pregnant and lactating females, puppies and kittens younger 6 weeks old.
Vemelcam should not be used simultaneously with other nonsteroidal anti-inflammatory drugs, glucocorticosteroids, diuretics, anticoagulants, aminoglycoside antibiotics, antiplatelet agents (acetylsalicylic acid, clopidogrel), selective serotonin reuptake inhibitors (fluoxetine) and other drugs characterized by a high degree of binding to serum proteins,
due to the likelihood of mutual enhancement of the nephrotoxic effect, as well as earlier than 24 hours after the end of the previous nonsteroidal anti-inflammatory drug, glucocorticosteroids are dovinephrotoxic drugs.
